Celiac Disease Eligible for CMDRP Research Funding for the First Time – Marilyn’s Message January 2023
2023 promises to be a year full of robust research, advocacy, and education efforts on behalf of our patient community.
Continue Reading2023 promises to be a year full of robust research, advocacy, and education efforts on behalf of our patient community.
Continue ReadingThe Celiac Disease Foundation is pleased to announce it will provide patient recruitment and eligibility screening for Anokion’s phase 1b/2 clinical trial for KAN-101.
Continue ReadingComments submitted to U.S. Preventive Services Task Force on Draft Research Plan: Preventive Services for Food Insecurity.
Continue ReadingThe Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.
Continue ReadingPatients Who Have Participated In a Celiac Disease Clinical Trial Needed for 2021 Patient Education & Advocacy Summit.
Continue ReadingThe first mice with characteristics of celiac disease have been developed at the University of Chicago Celiac Disease Center. For the first time researchers can observe celiac disease onset as the mouse’s immune system launches a coordinated attack against gluten.
Continue ReadingOn April 9, 2019, Marilyn G. Geller, CEO of the Celiac Disease Foundation, testified before the House Appropriations Subcommittee overseeing the funding for the Department of Health and Human Services, including the National Institutes of Health (NIH).
Continue ReadingIn this one-on-one interview with Gluten-Free Living Editorial Director Maureen McCarthy, CEO Marilyn Geller discusses the Foundation’s history, research and outreach goals, and the importance of partnering with GFL.
Continue Reading